Adjustable continence therapy (ACT®) balloons to treat neurogenic and non-neurogenic female urinary incontinence.
compression device
efficacy
intrinsic sphincter deficiency
safety
stress urinary incontinence
Journal
Neurourology and urodynamics
ISSN: 1520-6777
Titre abrégé: Neurourol Urodyn
Pays: United States
ID NLM: 8303326
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
revised:
31
08
2021
received:
25
07
2021
accepted:
07
09
2021
pubmed:
12
10
2021
medline:
25
3
2022
entrez:
11
10
2021
Statut:
ppublish
Résumé
To compare efficacy and safety between neurogenic and non-neurogenic women after adjustable continence therapy (ACT®) balloons implantation to treat stress urinary incontinence (SUI) due to intrinsic sphincter deficiency. In the present retrospective multicentric study, all neurogenic and non-neurogenic women implanted with ACT® balloons between 2000 and 2018 were considered for inclusion. Efficacy was compared 1 year after implantation, and women were allocated in three different groups as follows. Success: maximum 1 pad per day and patient's impression of improvement assessed using a numeral rating scale (NRS) ≥8/10. Improvement: decrease of daily pad use and/or NRS ≥5/10. Failure: increase or stability of daily pad use or NRS <5/10. Overall surgical complications and explantations were compared 1 year after implantation. Among the 277 included women, 51 presented with a neurologic underlying disease. Mean age at implantation was 68.5 years. There was no significant difference in efficacy between neurogenic and non-neurogenic women with a success rate of 39.2% and 36.3%, respectively (p = 0.69). Similarly, improvement rate was reported to be 31.4% and 33.6%, in neurogenic and non-neurogenic women, respectively (p = 0.92). The overall surgical complications rate (24% vs. 34.5%, p = 0.15) and the explantation rate (19.6% vs. 28.8%, p = 0.18) were not significantly different. ACT balloons may be proposed to treat mixed or SUI in females with ISD. Efficacy and safety profiles appear to be similar in both neurogenic and non-neurogenic patients.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
313-322Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
Buckley BS, Lapitan MCM, Epidemiology Committee of the Fourth International Consultation on Incontinence, Paris, 2008. Prevalence of urinary incontinence in men, women, and children-current evidence: findings of the Fourth International Consultation on Incontinence. Urology. 2010;76(2):265-270. doi:10.1016/j.urology.2009.11.078
Kinchen KS, Burgio K, Diokno AC, Fultz NH, Bump R, Obenchain R. Factors associated with women's decisions to seek treatment for urinary incontinence. J Womens Health (Larchmt). 2003;12(7):687-698. doi:10.1089/154099903322404339
Hunskaar S, Lose G, Sykes D, Voss S. The prevalence of urinary incontinence in women in four European countries. BJU Int. 2004;93(3):324-330. doi:10.1111/j.1464-410x.2003.04609.x
Milsom I, Coyne KS, Nicholson S, Kvasz M, Chen C-I, Wein AJ. Global prevalence and economic burden of urgency urinary incontinence: a systematic review. Eur Urol. 2014;65(1):79-95. doi:10.1016/j.eururo.2013.08.031
Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003;61(1):37-49. doi:10.1016/s0090-4295(02)02243-4
Podnar S, Vodušek DB. Lower urinary tract dysfunction in patients with peripheral nervous system lesions. Handb Clin Neurol. 2015;130:203-224. doi:10.1016/B978-0-444-63247-0.00012-2
Drake MJ, Apostolidis A, Cocci A, et al. Neurogenic lower urinary tract dysfunction: clinical management recommendations of the Neurologic Incontinence committee of the fifth International Consultation on Incontinence 2013. Neurourol Urodyn. 2016;35(6):657-665. doi:10.1002/nau.23027
Ford AA, Rogerson L, Cody JD, Aluko P, Ogah JA. Mid-urethral sling operations for stress urinary incontinence in women. Cochrane Database Syst Rev. 2017;7:CD006375. doi:10.1002/14651858.CD006375.pub4
Farag F, Koens M, Sievert K-D, De Ridder D, Feitz W, Heesakkers J. Surgical treatment of neurogenic stress urinary incontinence: a systematic review of quality assessment and surgical outcomes. Neurourol Urodyn. 2016;35(1):21-25. doi:10.1002/nau.22682
Phé V, Nguyen K, Rouprêt M, Cardot V, Parra J, Chartier-Kastler E. A systematic review of the treatment for female stress urinary incontinence by ACT® balloon placement (Uromedica, Irvine, CA, USA). World J Urol. 2014;32(2):495-505. doi:10.1007/s00345-013-1117-0
Ammirati E, Manassero A, Giammò A, Carone R. Management of male and female neurogenic stress urinary incontinence in spinal cord injured (SCI) patients using adjustable continence therapy. Urologia. 2017;84(3):165-168. doi:10.5301/uj.5000242
Mehnert U, Bastien L, Denys P, et al. Treatment of neurogenic stress urinary incontinence using an adjustable continence device: 4-year followup. J Urol. 2012;188(6):2274-2280. doi:10.1016/j.juro.2012.07.131
Ronzi Y, Le Normand L, Chartier-Kastler E, et al. Neurogenic stress urinary incontinence: is there a place for Adjustable Continence Therapy (ACTTM and ProACTTM, Uromedica, Plymouth, MN, USA)? A retrospective multicenter study. Spinal Cord. 2019;57(5):388-395. doi:10.1038/s41393-018-0219-3
Vayleux B, Luyckx F, Thélu S, et al. [Adjustable continence therapy in women, middle term follow-up and a new technique for balloon positioning]. Prog Urol. 2010;20(7):520-526. doi:10.1016/j.purol.2010.01.010